Biosymetrics

Biosymetrics company information, Employees & Contact Information

Explore related pages

Related company profiles:

BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines. We partner with leading healthcare and life science companies, such as Northwell Health, Janssen, Sema4, and Mt. Sinai, to increase our understanding of disease and find better drugs faster. We use a patent pending, machine learning technology called Contingent-AI™ to address bias detection and correction during pre-processing stages of machine learning and identify additional feature sets for analysis that are contingent upon decisions made during bias reduction. We combine this technology with an experimental practice that uniquely combines in silico and in vivo work to produce a faster, more precise set of predictive results for drug discovery research. We are a remote-first company with people clusters in Toronto and Boston. We are actively hiring. For more information, please visit our website at www.biosymetrics.com. #ArtificialIntelligence #AI #MachineLearning #Biotech #Healthcare #DataAnalytics #BigData #PrecisionMedicine #Pharma #LifeSciences #Genomics #DigitalHealth #DrugDiscovery #MedTech
Looking for a particular Biosymetrics employee's phone or email?

Biosymetrics Questions

News

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine - Yahoo Finance

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine Yahoo Finance

$1.85M NIH Grant Powers Lunai Bioworks' AI Platform to Combat Alcohol Disorder Affecting 19M Americans - Stock Titan

$1.85M NIH Grant Powers Lunai Bioworks' AI Platform to Combat Alcohol Disorder Affecting 19M Americans Stock Titan

Renovaro closes merger transaction with BioSymetrics - Pharmaceutical Business review -

Renovaro closes merger transaction with BioSymetrics Pharmaceutical Business review -

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine - Yahoo Finance

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine Yahoo Finance

Renovaro Inc. (RENB) Merges with BioSymetrics to Advance AI-Driven Cancer Research - Insider Monkey

Renovaro Inc. (RENB) Merges with BioSymetrics to Advance AI-Driven Cancer Research Insider Monkey

AI in Clinical Trial Market To Reach USD 22.3 Billion by 2033 - Market.us Media

AI in Clinical Trial Market To Reach USD 22.3 Billion by 2033 Market.us Media

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on - PharmiWeb.com

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on PharmiWeb.com

Lunai Bioworks advances biomarker discovery preclinical program in Parkinson’s - TipRanks

Lunai Bioworks advances biomarker discovery preclinical program in Parkinson’s TipRanks

BioSymetrics Launches Analytics Platform to Revolutionize AI in Biomedicine - HIT Consultant

BioSymetrics Launches Analytics Platform to Revolutionize AI in Biomedicine HIT Consultant

10M Global Parkinson's Patients: Lunai Bioworks Unveils AI Platform for Novel Treatment Discovery - Stock Titan

10M Global Parkinson's Patients: Lunai Bioworks Unveils AI Platform for Novel Treatment Discovery Stock Titan

BioSymetrics' Shiva Amiri says addressing lack of data standards key to scaling machine learning - BetaKit

BioSymetrics' Shiva Amiri says addressing lack of data standards key to scaling machine learning BetaKit

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline - PharmiWeb.com

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline PharmiWeb.com

AI Biodefense Pioneer Renovaro Transforms into Lunai Bioworks, Expanding Partnerships with Pfizer, Merck - Stock Titan

AI Biodefense Pioneer Renovaro Transforms into Lunai Bioworks, Expanding Partnerships with Pfizer, Merck Stock Titan

700 serum samples: Lunai Bioworks-led study identifies prognostic DMD biomarkers, RGMA and ANTXR2 - Stock Titan

700 serum samples: Lunai Bioworks-led study identifies prognostic DMD biomarkers, RGMA and ANTXR2 Stock Titan

RENB - Renovaro Latest Stock News & Market Updates - Stock Titan

RENB - Renovaro Latest Stock News & Market Updates Stock Titan

Top Biosymetrics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant